SAN DIEGO--(BUSINESS WIRE)--Aug. 22, 2006--Illumina, Inc. (NASDAQ:ILMN) announced today that investigators at Massachusetts General Hospital (MGH) and Harvard Medical School will utilize data from Sentrix(R) HumanHap300 BeadChips and Infinium(R) assay reagents to perform a 2,200-sample case/control whole-genome association study of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease.
